AZ Rides PACIFIC Wave To Be First In Early-Stage NSCLC
After Imfinzi's failure in the MYSTIC trial, AstraZeneca is very much back in the lung cancer game following the success of the PACIFIC study.
You may also be interested in...
Full PACIFIC data show strong overall survival benefit in all comers, though not in a post hoc analysis of those with low PD-L1 expression, about 20% of the population.
Keeping Track: Vitaros Reenters The Wilderness, Remoxy Gives It A Fourth Try, And Two Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.